Earnings Feed
Start Free
Home/Filings/3/0000950170-25-109842
3//SEC Filing

BridgeBio Pharma, Inc. 3

Accession 0000950170-25-109842

$BBIOCIK 0001869105operating
View on SEC.govCompany Profile

Filed

Aug 17, 8:00 PM ET

Accepted

Aug 18, 5:16 PM ET

Size

9.3 KB

Accession

0000950170-25-109842

Insider Transaction Report

Form 3
Period: 2025-08-11
BridgeBio Oncology Therapeutics, Inc.BBOT
BridgeBio Pharma, Inc.
10% Owner
Holdings

  • Common Stock

    13,805,126

  • Stock Option (Right to Buy)

    Exercise: $3.83Exp: 2030-05-18→ Common Stock (63,934 underlying)

  • Stock Option (Right to Buy)

    Exercise: $1.02Exp: 2030-05-18→ Common Stock (9,494 underlying)
BridgeBio Pharma LLC
10% Owner
Holdings

  • Stock Option (Right to Buy)

    Exercise: $3.83Exp: 2030-05-18→ Common Stock (63,934 underlying)

  • Common Stock

    13,805,126

  • Stock Option (Right to Buy)

    Exercise: $1.02Exp: 2030-05-18→ Common Stock (9,494 underlying)
Footnotes (3)
  • [F1]Shares are held by BridgeBio Pharma LLC ("BBIO LLC"). Voting and investment power over the shares held by BBIO LLC is exercised by its parent entity, BridgeBio Pharma, Inc. ("BBIO"). The board of directors of BBIO consists of Neil Kumar, Ph.D., Eric Aguiar, M.D., Jennifer E. Cook, Douglas A. Dachille, Ronald J. Daniels, Andrea J. Ellis, Fred Hassan, Charles Homcy, M.D., Andrew W. Lo, Ph.D., Frank P. McCormick, Ph.D., F.R.S., D.Sc., James C. Momtazee, Ali J. Satvat, Randal W. Scott, Ph.D., and Hannah A. Valantine, M.D. (each a BBIO director, and collective, the BBIO Directors"). None of the members of the board of directors of BBIO or BBIO LLC has individual voting or investment power with respect to such shares. Each of BBIO and the BBIO Directors disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act, except to the extent of its, his, or her pecuniary interest therein, if any.
  • [F2](Continued from Footnote 1) This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
  • [F3]The shares subject to such option are fully vested.

Documents

1 file

Issuer

BridgeBio Oncology Therapeutics, Inc.

CIK 0001869105

→
Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0001743881

Filing Metadata

Form type
3
Filed
Aug 17, 8:00 PM ET
Accepted
Aug 18, 5:16 PM ET
Size
9.3 KB
View on SEC.gov